Mona Shahlaei
Research Subjects
Mona Shahlaei has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Maryam Saeidifar
Department of Nanotechnology and Advanced Materials, Materials and Energy Research Center, Karaj, Iran
3 shared publications Ali Zamanian
2 shared publicationsAli Akbar Saboury
1 shared publicationAtefe Derakhshani
1 shared publicationIrena Kostova
1 shared publicationJohannes Karges
1 shared publication
Latest Publications
- 19 December 2023
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1301
Platinum-based drugs in cancer treatment: Expanding horizons and overcoming resistance
- 19 December 2023
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1301
Platinum-based drugs in cancer treatment: Expanding horizons and overcoming resistance
- 4 July 2022
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 110 (12) , 2636-2648
Sustained release of sulforaphane by bioactive extracellular vesicles for neuroprotective effect on chick model
Novel studies have shown neurological treatment possibilities with extracellular vesicles (EVs) as natural particles with a special composition that are produced by different cell types. Their stability, natural structure, composition, and bioavailability make them good candidates as drug vehicles. Here, EVs were isolated from amniotic fluid (AF) through differential centrifugation, and characterized for size (R2 = 0.99) kinetic model by non‐Fickian diffusion case II (n = 0.44, passive loading) and Fickian diffusion case I (n = 0.41, active and active‐passive loading). SFN‐loaded EVs (SFN@EVs; 11 μM: 103 nM) stimulated hPC‐12 cell proliferation. The gene expression analysis revealed that SFN@EVs could upregulate Nrf2 and reduce IL‐6 expression. Eventually, histopathological results of the coronal cross‐section of the chick embryos brain showed treatment with SFN@EVs. This treatment illustrated normality in the gray and white matter and the orientation of the bipolar neurons. Our findings showed EVs' potentially acting as a gene expression regulator in autism spectrum disorder.
- 4 July 2022
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 110 (12) , 2636-2648
Sustained release of sulforaphane by bioactive extracellular vesicles for neuroprotective effect on chick model
Novel studies have shown neurological treatment possibilities with extracellular vesicles (EVs) as natural particles with a special composition that are produced by different cell types. Their stability, natural structure, composition, and bioavailability make them good candidates as drug vehicles. Here, EVs were isolated from amniotic fluid (AF) through differential centrifugation, and characterized for size (R2 = 0.99) kinetic model by non‐Fickian diffusion case II (n = 0.44, passive loading) and Fickian diffusion case I (n = 0.41, active and active‐passive loading). SFN‐loaded EVs (SFN@EVs; 11 μM: 103 nM) stimulated hPC‐12 cell proliferation. The gene expression analysis revealed that SFN@EVs could upregulate Nrf2 and reduce IL‐6 expression. Eventually, histopathological results of the coronal cross‐section of the chick embryos brain showed treatment with SFN@EVs. This treatment illustrated normality in the gray and white matter and the orientation of the bipolar neurons. Our findings showed EVs' potentially acting as a gene expression regulator in autism spectrum disorder.
- 1 January 2020
- Published by Elsevier
- p. 123-157
Nanotechnology in gene delivery for neural regenerative medicine
- 1 January 2020
- Published by Elsevier
- p. 123-157
Nanotechnology in gene delivery for neural regenerative medicine